-
CapsoVision (CV) Misses Q2 EPS by 4c
-
CapsoVision launches AI Highlights for capsule endoscopy internationally
-
CapsoVision (CV) Reiterated at Speculative Buy by Benchmark After Q1 Results
-
CapsoVision (CV) Misses Q1 EPS by 4c
-
CapsoVision Inc (CV) PT Lowered to $10 at Benchmark, Estimates Adjusted
-
CapsoVision Inc (CV) PT Raised to $11 at Roth/MKM
-
CapsoVision submits FDA application for AI-assisted capsule endoscopy module
-
Benchmark Reiterates Speculative Buy Rating on CapsoVision Inc (CV)
-
CapsoVision (CV) Reports Q3 Loss of $0.17
-
CapsoVision seeks FDA breakthrough status for pancreatic cancer capsule
-
CapsoVision (CV) Misses Q2 EPS by 202c
-
Benchmark Starts CapsoVision Inc (CV) at Speculative Buy
-
Roth/MKM Starts CapsoVision Inc (CV) at Buy
-
Recent IPO CapsoVision (CV) Surges 140%
-
Capsovision (CV) Opens At $5, IPO Priced At $5
-
CapsoVision (CV) Prices 5.5M Share IPO at $5/sh
-
CapsoVision (CV) Files for 5.25M Share IPO at $5-$5.50/sh
-
CapsoVision (CV) Files for Proposed IPO

